Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model

J Immunol. 2003 May 1;170(9):4738-44. doi: 10.4049/jimmunol.170.9.4738.

Abstract

To better define the role of the various prostanoid synthases in the adjuvant-induced arthritis (AIA) model, we have determined the temporal expression of the inducible PGE synthase (mPGES-1), mPGES-2, the cytosolic PGES (cPGES/p23), and prostacyclin synthase, and compared with that of cyclooxygenase-1 (COX-1) and COX-2. The profile of induction of mPGES-1 (50- to 80-fold) in the primary paw was similar to that of COX-2 by both RNA and protein analysis. Quantitative PCR analysis indicated that induction of mPGES-1 at day 15 was within 2-fold that of COX-2. Increased PGES activity was measurable in membrane preparations of inflamed paws, and the activity was inhibitable by MK-886 to >or=90% with a potency similar to that of recombinant rat mPGES-1 (IC(50) = 2.4 microM). The RNA of the newly described mPGES-2 decreased by 2- to 3-fold in primary paws between days 1 and 15 postadjuvant. The cPGES/p23 and COX-1 were induced during AIA, but at much lower levels (2- to 6-fold) than mPGES-1, with the peak of cPGES/p23 expression occurring later than that of COX-2 and PGE(2) production. Prostacyclin (measured as 6-keto-PGF(1alpha)) was transiently elevated on day 1, and prostacyclin synthase was down-regulated at the RNA level after day 3, suggesting a diminished role of prostacyclin during the maintenance of chronic inflammation in the rat AIA. These results show that mPGES-1 is up-regulated throughout the development of AIA and suggest that it plays a major role in the elevated production of PGE(2) in this model.

Publication types

  • Comparative Study

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Animals
  • Antigens, Bacterial / administration & dosage
  • Arthritis, Experimental / enzymology*
  • Arthritis, Experimental / immunology
  • Arthritis, Experimental / pathology
  • Cyclooxygenase 2
  • Cytosol / drug effects
  • Cytosol / enzymology
  • Dinoprostone / biosynthesis*
  • Dinoprostone / genetics
  • Disease Models, Animal
  • Edema / enzymology
  • Edema / pathology
  • Epoprostenol / biosynthesis
  • Epoprostenol / genetics
  • Hindlimb
  • Indoles / pharmacology
  • Injections, Intradermal
  • Intracellular Membranes / drug effects
  • Intracellular Membranes / enzymology
  • Intramolecular Oxidoreductases / biosynthesis*
  • Intramolecular Oxidoreductases / genetics
  • Isoenzymes / genetics
  • Isoenzymes / physiology*
  • Microsomes / drug effects
  • Microsomes / enzymology*
  • Mycobacterium / immunology
  • Prostaglandin Antagonists / biosynthesis
  • Prostaglandin Antagonists / pharmacology
  • Prostaglandin-E Synthases
  • Prostaglandin-Endoperoxide Synthases / genetics
  • Prostaglandin-Endoperoxide Synthases / physiology*
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Sprague-Dawley
  • Up-Regulation* / genetics
  • Up-Regulation* / immunology

Substances

  • Adjuvants, Immunologic
  • Antigens, Bacterial
  • Indoles
  • Isoenzymes
  • Prostaglandin Antagonists
  • RNA, Messenger
  • MK-886
  • Epoprostenol
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Intramolecular Oxidoreductases
  • Prostaglandin-E Synthases
  • Dinoprostone